Search results
Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a...
WPRI Providence· 2 days agoTyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been ...
Genmab completes $1.8 billion acquisition of ProfoundBio By Investing.com
Investing.com· 4 days agoThe acquisition provides Genmab with worldwide rights to three clinical-stage candidates, including...
Scientists uncover new treatment pathway for rare 'spider web' childhood brain tumors
Medical Xpress· 1 day agoRather than a solid tumor, gliomatosis cerebri typically presents as a spider's web of cancer...
Gene Panel Predicts Early HER2+ Breast Cancer Prognosis
Medscape· 6 days agoPatients with early-stage HER2+ breast cancer could soon be offered less intensive treatment based...
Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024
KTLA-TV Los Angeles· 2 days agoShanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers ...
Nimbus reports positive data from Phase I/II solid tumour therapy trial
Clinical Trials Arena via Yahoo Finance· 2 days agoThe latest findings as of 18 March included data from 44 subjects in the dose...) achieved a...
Ipilimumab, a Pioneer Breakthrough in Cancer Treatment
Forbes· 6 days agoIn 2011, the first in a new generation of anticancer drugs called checkpoint inhibitors was...
FDA grants IND clearance for Abdera’s Phase I cancer therapy trial
Clinical Trials Arena via Yahoo Finance· 2 days agoThe high specificity of DLL3 expression on cancer cells combined with the unique action mechanism...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results from an ongoing Phase 1/2 trial evaluating its first-in-class costimulatory bispecific antibody, REGN7075 ...
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
FOX 23 News Albany· 5 days agoNovel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumors SAN JOSE, Calif., May 21, 2024 /PRNewswire/ -- Anixa Biosciences.